Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus TELMISARTAN AND AMLODIPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus TELMISARTAN AND AMLODIPINE.
AVALIDE vs TELMISARTAN AND AMLODIPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium ion influx across vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation and reduced blood pressure.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
Oral: one tablet containing telmisartan 40-80 mg and amlodipine 5-10 mg once daily; maximum dose: telmisartan 80 mg/amlodipine 10 mg daily.
None Documented
None Documented
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Telmisartan: terminal half-life ~24 hours (range 20-30 hours), supporting once-daily dosing. Amlodipine: terminal half-life ~30-50 hours (mean 35 hours), achieving steady state after 7-8 days; prolonged half-life allows once-daily dosing.
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Telmisartan: primarily excreted unchanged in feces (97%) via biliary elimination; renal excretion accounts for <2%. Amlodipine: extensively metabolized in liver; 60% of metabolites excreted renally, 20-25% in feces. Unchanged amlodipine in urine: <10%.
Category C
Category D/X
ARB and Thiazide Diuretic Combination
ARB